Month: August 2014

iCeMS and CiRA team induces mouse skeletal muscle stem cells with miRNA, potential for treatment of muscular dystrophy

A team around Takahiko SATO identified miR-195 and miR-497 to induce cell cycle arrest in adult skeletal muscle. Transplantation of cultured MuSCs treated with miR-195/497 contributed to regenerating muscles of dystrophin-deficient mice, indicating the potential utility of miR-195/497 for stem cell therapy of muscular dystrophy. China Bio news release, August 18, 2014

Interdisciplinary team succeeds to control leg movement without assistance of spinal cord, directed towards patients with spinal cord injury

A group around Yukio NISHIMURA from the National Institute for Physiological Sciences, Okazaki, succeeded to install a computer-based artificial neural connection (ANC) tot he lumbar locomotor center, controlling walking, which bypasses the spinal cord. The system was successfully tested with human volunteers. JST news release, August 14, 2014

Silk modified by azido-substituted analugues of L-phenylalanine produced by transgenic silkworm

Hidetoshi TERAMOTO et al. at NIAS have used transgenic silkworms that expressed a mutant of phenylalanyl-tRNA synthetase with expanded substrate recognition capabilities to produce AzPhe-incorporated silk fibroin. The larvae were fed p-chloro-, p-bromo-, and p-azido-substituted analogues of l-phenylalanine. The activated silk fibroin could be a versatile platform to produce “clickable” silk materials. Nikkei Biotech news […]

NEDO consortium develops information support system for cancer therapy and iPS-based cell transplantation

In the first program, a „cancer diagnosis and treatment navigation system“ will be established which combines data from MRI, CT and medical information to improve patient information and refine treatment. In the second program, it will be attempted to monitor post-transplantation efficiency of transplanted cornea epithelial sheets. The two programs will be carried out by […]

Yamaguchi University starts clinical tests on autologous bone marrow cell therapy (ABMi) for treatment of liver cirrhosis

This treatment is intended for decompensated cirrhosis patients. About 30 ml of bone marrow fluid will be collected from about 10 patients, cultured for about three weeks to increase bone marrow mesenchymal stem cells, and then intravenously drip-infused in the patients’ vein. PI is Professor Sakai. JST news release, August 6, 2014

NEDO consortium develops ECM cement production with 60 % reduced energy consumption and CO2 emissions

The consortium made up of Takenaka Co., Kajima Co., D.C. Co., Nippon Steel and Sumitomo Cement Co. have developed an ECM (Energy CO2 Minimum) cement where energy consumption and C=2 emissions were reduced by more than 60 %, by optimizing particle size composition, component configuration and construction technology. NEDO news release, August 5, 2014

Scroll to top